Movement Disorders in Autoimmune Encephalitis a Cohort
Objective: To analyze the clinical profile of patients with suspected autoimmune encephalitis. Background: Autoimmune encephalitis (AE) is a disease characterized by a diverse range of…A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Parkinson’s Disease
Objective: Glunomab, a monoclonal antibody designed to inhibit the interaction between tissue plasminogen activator (tPA) and the N-methyl-D-aspartate receptor (NMDAr), has demonstrated therapeutic potential across…Severe Anti-NMDAR Encephalitis After the Covid 19 Cross-vaccination in three young women
Objective: To describe three severe cases of anti-NMDAR encephalitis in young females after the COVID-19 cross-vaccination. Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most recognized…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Huntington’s Disease Pathogenesis, Molecular Factors, and Potential for Combinatorial Therapies: A Focus on BDNF and NMDA Receptor Therapies
Objective: This paper outlines current therapeutic options for HD, and ultimately suggests taking a combinatorial therapeutic approach to slow HD progression by simultaneously treating multiple…Complex movement disorder presentations of autoimmune encephalitis – recovery at 4 weeks versus 4 years
Objective: The goal is to learn from different presentations of Autoimmune Encephalitis (AIE) so that we consider the diagnosis more quickly, pursue the work-up judiciously…24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)
Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD. Background: HD…Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…GRIN2D is a cause of autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…Isolated craniocervical dystonia without neuropsychiatric manifestations associated with NMDA-receptor antibodies
Objective: N-methyl-D-aspartate receptor (NMDAR) encephalitis classically spans neuropsychiatric disturbance, autonomic dysfunction and salient movement disorders. Attenuated presentations are increasingly recognised; however, presentations with an isolated…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.